On August 25, 2025 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, reported that it will present new data at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, taking place September 6 – 9 in Barcelona, Spain (Press release, Natera, AUG 25, 2025, View Source [SID1234655474]). The presentations underscore the strong clinical utility of Signatera in lung cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
An analysis of early-stage, resectable non-small cell lung cancer (NSCLC) patients will be featured in an oral presentation, demonstrating that Signatera status in the post-surgical molecular residual disease window is highly prognostic of recurrence-free survival and overall survival. Signatera Genome was used for this study, and the data highlights the potential of Signatera to individualize patient care by improving stratification of post-surgical recurrence risk.
"Our data at WCLC reinforces the strong clinical utility of Signatera in lung cancer, which is the most common form of cancer diagnosed worldwide," said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer at Natera. "Notably, we look forward to sharing data on Signatera Genome that highlights its prognostic value for risk stratification in patients with early-stage, resectable NSCLC."
Full list of presentations at WCLC include:
September 7, 3:22 PM CEST | Presentation # MA03.02 (Oral Presentation)
Presenter: Gaston Becharano, M.D.
Clinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC
September 8, 10:30 AM CEST | Presentation # P2.06.78
Presenter: Daniel Rosas, M.D.
Using a Personalized, Tumor-Informed Circulating DNA (ctDNA) to Monitor Treatment Outcomes in Lung Cancer
September 9, 10:00 AM CEST | Presentation # P3.18.04
Presenter: Ken Masuda, M.D.
MRDSEEKER (JCOG2111A): A Prospective Study to Evaluate MRD and Its Association With Prognosis in Curative-Intent NSCLC